S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why

GSK (GSK) Stock Forecast, Price & News

$34.36
-0.26 (-0.75%)
(As of 06/7/2023 ET)
Compare
Today's Range
$34.23
$34.70
50-Day Range
$33.60
$38.32
52-Week Range
$28.47
$44.75
Volume
2.23 million shs
Average Volume
3.30 million shs
Market Capitalization
$70.35 billion
P/E Ratio
4.15
Dividend Yield
3.96%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.56mentions of GSK in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.28%
From $3.66 to $3.89 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

222nd out of 981 stocks

Pharmaceutical Preparations Industry

97th out of 462 stocks


GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
GSK wins EU approval for RSV vaccine Arexvy
UPDATE 1-EU authorises GSK's RSV vaccine
Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
US Approves Second RSV Vaccine
Market Digest: MKL, GSK, NFG
What To Expect From GSK In 2023
See More Headlines

GSK Price History

GSK Company Calendar

Ex-Dividend for 4/13 Dividend
2/23/2023
Dividend Payable
4/13/2023
Last Earnings
4/26/2023
Ex-Dividend for 7/13 Dividend
5/18/2023
Today
6/08/2023
Dividend Payable
7/13/2023
Next Earnings (Confirmed)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
69,400
Year Founded
2000

Profitability

Net Income
$18.50 billion
Pretax Margin
16.53%

Debt

Sales & Book Value

Annual Sales
$36.28 billion
Cash Flow
$4.47 per share
Book Value
$5.79 per share

Miscellaneous

Outstanding Shares
2,047,470,000
Free Float
1,842,727,000
Market Cap
$70.35 billion
Optionable
Optionable
Beta
0.67

Social Links


Key Executives

  • Emma N. WalmsleyEmma N. Walmsley
    Chief Executive Officer & Executive Director
  • Julie Brown
    Chief Financial Officer & Executive Director
  • Tony Wood
    Chief Scientific Officer
  • Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Amy Altshul
    SVP-Legal, Research & Development













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 on January 1st, 2023. Since then, GSK shares have decreased by 2.2% and is now trading at $34.36.
View the best growth stocks for 2023 here
.

Are investors shorting GSK?

GSK saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,720,000 shares, a decrease of 5.8% from the April 30th total of 3,950,000 shares. Based on an average trading volume of 2,880,000 shares, the short-interest ratio is currently 1.3 days. Currently, 0.2% of the company's shares are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) posted its earnings results on Wednesday, April, 26th. The pharmaceutical company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. The pharmaceutical company had revenue of $8.45 billion for the quarter, compared to the consensus estimate of $8.55 billion. GSK had a trailing twelve-month return on equity of 43.27% and a net margin of 47.85%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, April 26th. Shareholders of record on Friday, May 19th will be paid a dividend of $0.3475 per share on Thursday, July 13th. This represents a $1.39 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, May 18th. This is an increase from the stock's previous quarterly dividend of $0.34.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.36 per share and currently has a dividend yield of 3.97%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 16.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 34.96% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $1.90-$1.96 for the period, compared to the consensus EPS estimate of $3.68. The company issued revenue guidance of $37.75 billion-$38.47 billion, compared to the consensus revenue estimate of $35.72 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a number of institutional and retail investors. Top institutional investors include Dodge & Cox (3.40%), FMR LLC (0.76%), JTC Employer Solutions Trustee Ltd (0.68%), Fisher Asset Management LLC (0.65%), Price T Rowe Associates Inc. MD (0.60%) and Arrowstreet Capital Limited Partnership (0.53%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $34.36.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $70.35 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.28 on an earnings per share basis.

How many employees does GSK have?

The company employs 69,400 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -